In one paragraphArticle in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Marta LafuenteGroup of Applied Clinical Research in Hematology, Cancer Research Program Hospital del Mar Research Institute, 08003 Barcelona, Spain.ORCID 0009-0003-2907-5049 Ramón Diez-FeijóoGroup of Applied Clinical Research in Hematology, Cancer Research Program Hospital del Mar Research Institute, 08003 Barcelona, Spain.ORCID 0000-0003-3137-3443 Marta García-RecioDepartment of Hematology, University Hospital Son Espases/Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.
Nieves Garcia-GisbertGroup of Applied Clinical Research in Hematology, Cancer Research Program Hospital del Mar Research Institute, 08003 Barcelona, Spain.ORCID 0000-0002-8185-9786 Maria Concepción Fernández-RodríguezGroup of Applied Clinical Research in Hematology, Cancer Research Program Hospital del Mar Research Institute, 08003 Barcelona, Spain.ORCID 0000-0002-5853-0843 Raquel LongarónGroup of Applied Clinical Research in Hematology, Cancer Research Program Hospital del Mar Research Institute, 08003 Barcelona, Spain.
Junjie JiGroup of Applied Clinical Research in Hematology, Cancer Research Program Hospital del Mar Research Institute, 08003 Barcelona, Spain.
Bárbara Tazon-VegaGroup of Applied Clinical Research in Hematology, Cancer Research Program Hospital del Mar Research Institute, 08003 Barcelona, Spain.
Sergio PinzónDepartment of Hematology, Hospital del Mar, 08003 Barcelona, Spain.
Lierni Fernández-IbarrondoGroup of Applied Clinical Research in Hematology, Cancer Research Program Hospital del Mar Research Institute, 08003 Barcelona, Spain.ORCID 0000-0003-2612-0484 Blanca Sánchez-GonzálezGroup of Applied Clinical Research in Hematology, Cancer Research Program Hospital del Mar Research Institute, 08003 Barcelona, Spain.
Laura CamachoGroup of Applied Clinical Research in Hematology, Cancer Research Program Hospital del Mar Research Institute, 08003 Barcelona, Spain.
Joan GibertGroup of Applied Clinical Research in Hematology, Cancer Research Program Hospital del Mar Research Institute, 08003 Barcelona, Spain.
Antonio GutierrezDepartment of Hematology, University Hospital Son Espases/Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain.ORCID 0000-0001-9062-077X Beatriz BellosilloGroup of Applied Clinical Research in Hematology, Cancer Research Program Hospital del Mar Research Institute, 08003 Barcelona, Spain.
Antonio SalarGroup of Applied Clinical Research in Hematology, Cancer Research Program Hospital del Mar Research Institute, 08003 Barcelona, Spain.ORCID 0000-0002-4652-4825 Funding
Agència de Gestió d'Ajuts Universitaris i de Recerca 2021SGR628Gilead Sciences (Spain) GLD18/00117Instituto de Salud Carlos III FI24/00294Instituto de Salud Carlos III PI19/00034Ministerio de Universidades FPU21/02671
6 · The paper itselfAbstract
introductionFollicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Approximately 20% of patients experience early relapse within 24 months (POD24) of immunochemotherapy (ICT), a subgroup associated with poor prognosis and not well-identified by current prognostic indices. Given that tumor mutational burden (TMB) has been associated with outcome in various cancers, we investigated its potential as a prognostic biomarker in FL.
methodsTMB was estimated by next-generation sequencing using a 409-gene panel in a cohort of 119 patients diagnosed with FL grades 1-3A and treated with frontline immunotherapy or ICT.
resultsAlthough TMB was not associated with clinical variables in non-transformed FL patients, higher TMB values were observed in patients harboring the t(14;18) translocation, mutations in
conclusionsThese findings support the potential of TMB as a prognostic biomarker in FL, providing molecular understanding beyond established clinical indices and aiding in the identification of patients at higher risk of early progression following ICT.
Indexed as
18) translocationfollicular lymphomanext generation sequencingprognostic biomarkert(14tumor mutational burden
Identifiers
PMID41827672
PMCPMC12985221
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390